Free cash flow volatility is pronounced, with a negative 26.1% FCF margin in 2025Q2 driven by a $9.9M outflow in working capital.
| Cash from Operations | 2.53M | 14.64M | 2.28M | -9.16M | -54.66K | 5.33M | 9.31M | 11.82M |
| Operating CF Margin % | - | 15.1% | 2.34% | -8.87% | -0.05% | 5.98% | 11.69% | 15.61% |
| Operating CF Growth % | -1189.6% | 543.16% | 124.84% | -16662.78% | -101.03% | -42.78% | -21.23% | - |
| Net Income | 18.55M | 10.84M | 11.59M | 6.18M | 19.99M | 19.05M | 15.43M | 15.48M |
| Depreciation & Amortization | 1.02M | 571.03K | 470.99K | 563.46K | 622.47K | 523.43K | 509.22K | 567.77K |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes | 0 | -642.63K | -370.48K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -5.99M | 3.9M | 2.18M | 4.51M | 15.28K | 2.85K | -9.53K | 6.71M |
| Working Capital Changes | -11.05M | -27.97K | -11.6M | -20.41M | -20.68M | -14.25M | -6.62M | -10.94M |
| Change in Receivables | -13.91M | -3.21M | -14.02M | -7.12M | -20.07M | -13.64M | -4.71M | -11.09M |
| Change in Inventory | 575.72K | 165.76K | -528.63K | 35.03K | 105.12K | -219.79K | 802.61K | -170.6K |
| Change in Payables | 0 | 932.49K | 185.9K | -3.37M | 4.91M | 5.34M | -4.23M | 0 |
| Cash from Investing | -16.84M | -20.42M | -12.46M | -8.62M | -833.82K | -16.09M | -8.9M | -7.57M |
| Capital Expenditures | -324.57K | -133.55K | -1.18M | -2.7M | -850.23K | -16.12M | -8.95M | -12.3K |
| CapEx % of Revenue | 0.18% | 0.14% | 1.22% | 2.61% | 0.82% | 18.1% | 11.24% | 0.02% |
| Acquisitions | 0 | -89.72K | 0 | 658.46K | 16.41K | 25.2K | 50.6K | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | -16.51M | -15.9M | -11.63M | 23.15K | 0 | 0 | 0 | -7.56M |
| Cash from Financing | 12.82M | 6.21M | 706.13K | 37.25M | 1.86M | 1.71M | 923.77K | -4.2M |
| Debt Issued (Net) | 6.62M | 6.41M | 706.13K | 2.08M | 1.86M | 434.52K | 579.03K | 0 |
| Equity Issued (Net) | -200K | -200K | 0 | 1000K | 0 | 1000K | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -200K | -200K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 6.4M | 0 | 0 | 635.31K | 0 | 0 | 344.74K | -4.2M |
| Net Change in Cash | -71.78K | 362.07K | -9.81M | 18.59M | 961.94K | -8.84M | 1.23M | -794.34K |
| Free Cash Flow | 12.11M | 14.5M | -2.41M | -11.86M | -904.89K | -10.79M | 356.12K | 11.8M |
| FCF Margin % | 6.59% | 14.97% | -2.48% | -11.48% | -0.87% | -12.12% | 0.45% | 15.59% |
| FCF Growth % | 157.8% | 701.59% | 79.68% | -1210.85% | 91.62% | -3130.93% | -96.98% | - |
| FCF per Share | 37.96 | 52.99 | -10.07 | -50.67 | -3.83 | -44.71 | 1.48 | 59.02 |
| FCF Conversion (FCF/Net Income) | 0.65x | 1.35x | 0.20x | -1.47x | -0.00x | 0.28x | 0.60x | 0.76x |
| Interest Paid | 129.86K | 247.62K | 250.78K | 194.67K | 180.74K | 137.16K | 97.79K | 0 |
| Taxes Paid | 0 | 3.66M | 3.58M | 5.7M | 5.04M | 4.36M | 3.9M | 0 |
Working Capital Liquidity Risk
According to recent financial disclosures, MHUA's operating cash flow to net income ratio reached a concerning -6.30 in 2025Q2, highlighting a severe disconnect between reported accounting profits and the actual cash generated from core operations during the most recent quarterly reporting period.
The persistent inability to convert net income into operating cash flow suggests that the company's earnings quality is significantly compromised by non-cash accruals or delayed collections. Investors should monitor whether this divergence reflects structural issues in revenue recognition or simply an aggressive buildup of receivables that may never materialize as cash.
As reported in the company's cash flow statements, MHUA's free cash flow margin plummeted to -26.1% in 2025Q2, marking a sharp reversal from the positive 26.2% margin achieved in 2024Q4 and underscoring the extreme instability inherent in the firm's current cash generation profile.
The erratic nature of free cash flow suggests that the business model is highly sensitive to working capital swings rather than consistent operational performance. This volatility makes it difficult to rely on internal cash generation to fund future growth or maintain the current dividend policy, if any.
Based on the provided quarterly data, MHUA experienced a massive working capital outflow of $9.9M in 2025Q2, which directly mirrors the negative operating cash flow and indicates that the company is struggling to manage its cash conversion cycle effectively in the current environment.
The recurring negative working capital changes suggest that the company is effectively financing its customers' operations through extended payment terms. This trend warrants further investigation into the credit quality of the hospital systems MHUA serves and the potential for future write-downs of aged accounts receivable.
Data from the last ten quarters reveals a consistent pattern where net income frequently exceeds operating cash flow, with the cumulative gap suggesting that reported profitability may be significantly overstated relative to the actual cash liquidity available to the firm's balance sheet over time.
This long-term divergence implies that the company's growth has been largely funded by accounting accruals rather than organic cash generation. Analysts should be wary of this trend, as it often precedes a period of liquidity stress when the underlying receivables eventually fail to convert into cash.
Quick answers to the most common questions about buying MHUA stock.
Meihua International Medical Technologies Co., Ltd. (MHUA) generated $14.6M in net cash from operating activities in 2024. This reflects the cash generated directly from core business operations.
Meihua International Medical Technologies Co., Ltd. (MHUA) generated $14.5M in free cash flow in 2024. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
Meihua International Medical Technologies Co., Ltd. (MHUA) spent $0.1M on capital expenditures in 2024. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2024, Meihua International Medical Technologies Co., Ltd. (MHUA) spent $0.2M on share repurchases. This shows the company's commitment to returning capital to its equity investors.